OBJECTIVE: To evaluate the efficacy and prognostic validity for disease-specific survival (DSS) of the eighth edition American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis (TNM) staging system (TNM-8) compared to the seventh edition (TNM-7) in patients with differentiated thyroid carcinoma (DTC). METHODS: The seventh and eighth editions of the TNM staging system were applied to 1613 DTC patients who underwent thyroid surgery between 1996 and 2003. The proportion of variation explained and Harrell's c-index were evaluated to compare the predictive capability of DSS. RESULTS: The mean age of the patients was 44.7 years, and the median follow-up period was 11.2 years. When TNM-8 was applied, 63% of T3 and 3% of N1b DTCs were downgraded to T1/T2 and N1a, respectively. About 38% of patients were downstaged according to TNM-8. The 10-year DSS rates in TNM-7 stages I, II, III, and IV were 99.7%, 98.2%, 98.8%, and 83.2%, respectively. Those in TNM-8 stages I, II, III, and IV were 99.6%, 95.4%, 72.3%, and 48.6%, respectively. The proportion of variation explained values of TNM-7 and TNM-8 were 6.0% and 7.0%, respectively. The Harrell's c-index of TNM-7 was 0.86 and that of TNM-8 was 0.88. CONCLUSIONS: A significant number of patients were reclassified to lower stages with the application of TNM-8 compared to TNM-7. Applying TNM-8 could improve the accuracy of the staging system for predicting DSS in patients with DTC.
OBJECTIVE: To evaluate the efficacy and prognostic validity for disease-specific survival (DSS) of the eighth edition American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis (TNM) staging system (TNM-8) compared to the seventh edition (TNM-7) in patients with differentiated thyroid carcinoma (DTC). METHODS: The seventh and eighth editions of the TNM staging system were applied to 1613 DTC patients who underwent thyroid surgery between 1996 and 2003. The proportion of variation explained and Harrell's c-index were evaluated to compare the predictive capability of DSS. RESULTS: The mean age of the patients was 44.7 years, and the median follow-up period was 11.2 years. When TNM-8 was applied, 63% of T3 and 3% of N1b DTCs were downgraded to T1/T2 and N1a, respectively. About 38% of patients were downstaged according to TNM-8. The 10-year DSS rates in TNM-7 stages I, II, III, and IV were 99.7%, 98.2%, 98.8%, and 83.2%, respectively. Those in TNM-8 stages I, II, III, and IV were 99.6%, 95.4%, 72.3%, and 48.6%, respectively. The proportion of variation explained values of TNM-7 and TNM-8 were 6.0% and 7.0%, respectively. The Harrell's c-index of TNM-7 was 0.86 and that of TNM-8 was 0.88. CONCLUSIONS: A significant number of patients were reclassified to lower stages with the application of TNM-8 compared to TNM-7. Applying TNM-8 could improve the accuracy of the staging system for predicting DSS in patients with DTC.
Authors: Ashok R Shaha; Jocelyn C Migliacci; Iain J Nixon; Laura Y Wang; Richard J Wong; Luc G T Morris; Snehal G Patel; Jatin P Shah; R Michael Tuttle; Ian Ganly Journal: Surgery Date: 2018-11-08 Impact factor: 3.982
Authors: R Forleo; N Fralassi; F Maino; M Capezzone; L Brilli; T Pilli; S Cantara; M G Castagna Journal: J Endocrinol Invest Date: 2020-05-09 Impact factor: 4.256
Authors: G Sapuppo; M Tavarelli; M Russo; P Malandrino; A Belfiore; R Vigneri; G Pellegriti Journal: J Endocrinol Invest Date: 2018-03-16 Impact factor: 4.256
Authors: Moran Amit; Samantha Tam; Mongkol Boonsripitayanon; Maria E Cabanillas; Naifa L Busaidy; Elizabeth Gardner Grubbs; Stephen Y Lai; Neil D Gross; Erich M Sturgis; Mark E Zafereo Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-02-01 Impact factor: 6.223
Authors: Sana A Ghaznavi; Ian Ganly; Ashok R Shaha; Crystal English; Jonathan Wills; R Michael Tuttle Journal: Thyroid Date: 2018-08-02 Impact factor: 6.568
Authors: Min Ji Jeon; Won Gu Kim; Tae Hyuk Kim; Hee Kyung Kim; Bo Hyun Kim; Hyon Seung Yi; Eun Sook Kim; Hosu Kim; Young Nam Kim; Eun Heui Kim; Tae Yong Kim; Sun Wook Kim; Ho Cheol Kang; Jae Hoon Chung; Young Kee Shong; Won Bae Kim Journal: Endocrinol Metab (Seoul) Date: 2017-11-22